The leukemia drug Venetoclax has been granted "priority review" status by the U.S. Food and Drug Administration (FDA).
The Food and Drug Administration has approved Roche's Cottelic drug to be used as a combination treatment for advanced melanoma skin cancer.
Roche's phase 2 studies for cancer drug Atezolizumab shows successful results in reducing tumors.
